All In Biotech

NDA 214012 · Novartis

Leqvio

Inclisiran Sodium · Subcutaneous

NovelOrphan

CDER novel approval, Dec 22, 2021: To treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease as an add-on therapy

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 22, 2021

Approved uses

4

Original approval plus efficacy supplements

Registered trials

56

24 Phase 3, 17 recruiting

FAERS reports

8,446

3,638 serious, 238 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 19, 2026.

LEQVIO ® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors as an add-on to statin therapy. LEQVIO is a small interfering RNA (siRNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. ( 1 ) adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). ( 1 ) Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy. ( 1 )

Mechanism: Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisiran utilizes the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 12, 2026 Supplement 18 · Efficacy · priority review OrphanLetterLabel
  • Feb 12, 2026 Supplement 17 · Efficacy · priority review LetterLabel
  • Jul 31, 2025 Supplement 16 · Efficacy LetterLabel
  • Dec 22, 2021 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • LEQVIO · INCLISIRAN SODIUM EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Inclisiran" as an intervention, any sponsor and status, largest first.

All 56 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • arthralgia908
  • myalgia706
  • injection site pain600
  • low density lipoprotein increased529
  • pain in extremity510
  • drug ineffective442
  • fatigue440
  • pain423
  • diarrhoea389
  • dyspnoea375
  • headache330
  • rash299

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20191
20201
202132
2022910
20232,224
20241,909
20251,933
20261,435

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Leqvio (Inclisiran Sodium)

2024 spending

$14.4M

Beneficiaries

2,681

4,425 claims

Per beneficiary

$5,364

$2,162.36 per unit

View as table
YearSpending
2020$0
2021$0
2022$3,796,981
2023$10,564,892
2024$14,379,723

Part B: Leqvio (Inclisiran Sodium) · HCPCS J1306

2024 spending

$296M

Beneficiaries

48,298

87,716 claims

Per beneficiary

$6,135

2024 ASP limit $12.16 per unit

View as table
YearSpending
2020$0
2021$0
2022$28,475,760
2023$143,175,005
2024$296,288,761

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 84 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.